AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL

Exclusion Criteria

• •Prior solid organ transplantation or SCT
• •Significant or extensive history of cardiovascular disease such as New York Heart Association Class III or IV cardiac disease or Objective Assessment Class C or D, myocardial infarction within the last 6 months prior to the start of Cycle 1, unstable arrhythmias, or unstable angina
• •History or presence of an abnormal ECG that is clinically significant in the investigator's opinion
• •Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma):
• •* Absolute neutrophil count \<1.0 × 10⁹/L.
• •* Platelet count \<75 × 10⁹/L
• •* Serum AST and ALT ≥ 2.5 x ULN
• •* Total bilirubin ≥ 1.5 x ULN
• •* Serum creatinine clearance \< 30 mL/min (using Cockcroft-Gault formula)
• •Any active infection within 7 days prior to Cycle 1 Day 1 that would impact participant safety
• •Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \[HBsAg\] serology)：Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HbsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing every month and appropriate antiviral therapy as indicated
• •Positive test results for hepatitis C (hepatitis C virus \[HCV\] antibody serology testing)：Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA
• •Participants with a history of progressive multifocal leukoencephalopathy
• •Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 months after final dose of treatment
• •Participants with uncontrolled coagulation disorders, connective tissue diseases, severe infectious diseases
• •Other concurrent and uncontrolled medical conditions that, in the opinion of the investigator, would affect the patient's participation in the study